CAPTRUST Financial Advisors’s Corcept Therapeutics CORT Stock Holding History
Bought
Maintained
Sold
Other funds holding CORT
ISL
VPM
VCM
PA
CAPTRUST Financial Advisors's CORT Position: Q1 2026 in Review
CAPTRUST Financial Advisors increased its Corcept Therapeutics (CORT) stake by 153% in Q1 2026, buying an estimated $537K and bringing the position to 23,795 shares worth $959K. The position accounts for ﹤0.01% of the portfolio, ranked #1640.
CAPTRUST Financial Advisors first reported a position in CORT in Q3 2020 and has held it in 23 quarters since. The position peaked at $5.74M in Q4 2024. 351 funds tracked by Wall St. Rank hold CORT as of Q1 2026.
- CAPTRUST Financial Advisors held 23,795 shares of Corcept Therapeutics worth $959K as of Q1 2026.
- CAPTRUST Financial Advisors bought 14,373 Corcept Therapeutics shares in Q1 2026, an estimated $537K.
- Corcept Therapeutics made up ﹤0.01% of CAPTRUST Financial Advisors's portfolio in Q1 2026, its #1640 holding.
- CAPTRUST Financial Advisors first reported a position in Corcept Therapeutics in Q3 2020 and has held it in 23 quarters since.
- CAPTRUST Financial Advisors's Corcept Therapeutics position peaked at $5.74M in Q4 2024.
- 351 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q1 2026.
Based on CAPTRUST Financial Advisors's 13F filing for Q1 2026, filed 15 May 2026.